Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Multi-Center, Open-Label, Single-Arm Study to Evaluate the Clinical Validity and Safety of IOP Injection for Magnetic Resonance Imaging (MRI) Contrast Agent in Hepatocellular Carcinoma (HCC)

NCT03407495 is registered in ClinicalTrials.gov with MegaPro Biomedical Co. Ltd. as lead sponsor.

NCT NCT03407495
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03407495 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Multi-Center, Open-Label, Single-Arm Study to Evaluate the Clinical Validity and Safety of IOP Injection for Magnetic Resonance Imaging (MRI) Contrast Agent in Hepatocellular Carcinoma (HCC)
Lead sponsor
MegaPro Biomedical Co. Ltd.
Phase
Phase 2
Overall status
Completed
Start date
November 22, 2018
Completion date
October 30, 2020
Enrollment
52 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

magnetic resonance imaging